Victory Pharma scores deal with Hi-Tech Pharmacal

Share this article:
Victory Pharma has inked a deal with Hi-Tech Pharmacal for exclusive US commercial license rights to its Naprelan (naproxen sodium) formulation for the treatment of arthritis. The product will be marketed through Victory's physician-based field sales force deployed throughout the US with plans for sales force expansion under way.  

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.